Logo

DRIO

DarioHealth Corp.

DRIO

DarioHealth Corp. • NASDAQ
$11.94 ▼ -0.25% (-0.03)
Market Cap $543.23 M
52w High $31.00
52w Low $5.93
Dividend Yield 0%
P/E -1.1
Volume 8.30K
Outstanding Shares 45.50M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $5.007M ▼ $12.499M ▲ $-2.077M ▲ -41.477% ▲ $0.38 ▲ $-8.733M ▼
Q2-2025 $5.369M ▼ $-5.803M ▼ $-12.99M ▼ -241.944% ▼ $-0.2 ▼ $-8.398M ▼
Q1-2025 $6.752M ▼ $-5.527M ▲ $-9.227M ▲ -136.656% ▼ $0.14 ▲ $-8.153M ▲
Q4-2024 $7.604M ▲ $-6.178M ▲ $-9.632M ▲ -126.67% ▲ $-0.26 ▼ $-8.382M ▲
Q3-2024 $7.423M $-6.809M $-12.33M -166.105% $0.36 $-10.324M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $32.129M ▲ $117.727M ▲ $42.793M ▼ $74.934M ▲
Q2-2025 $21.954M ▼ $108.325M ▼ $44.339M ▲ $63.986M ▼
Q1-2025 $27.854M ▼ $115.6M ▼ $41.901M ▼ $73.699M ▲
Q4-2024 $28.461M ▲ $118.884M ▲ $46.865M ▼ $72.019M ▲
Q3-2024 $15.547M $109.953M $51.442M $58.511M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-2.077M ▲ $-7.35M ▼ $-41K ▲ $17.393M ▲ $9.957M ▲ $-7.391M ▼
Q2-2025 $-12.99M ▼ $-6.031M ▲ $-44K ▼ $124K ▼ $-5.9M ▼ $-6.075M ▲
Q1-2025 $-9.227M ▲ $-6.673M ▲ $-31K ▼ $6.815M ▼ $90K ▼ $-6.704M ▲
Q4-2024 $-9.632M ▲ $-6.732M ▲ $-21K ▲ $18.325M ▲ $11.554M ▲ $-6.753M ▲
Q3-2024 $-12.33M $-7.357M $-32K $0 $-7.391M $-7.389M

Revenue by Products

Product Q4-2024Q1-2025Q2-2025Q3-2025
Service
Service
 $10.00M ▲$0 ▼$0 ▲$0 ▲

Five-Year Company Overview

Income Statement

Income Statement DarioHealth is still very much in the investment and build‑out phase. Revenue has been growing from a very small base and is now meaningfully higher than a few years ago, but still modest compared with operating costs. Gross profit is positive, which means the core service can generate value once scale is reached, but the company continues to post sizable operating and net losses every year. Losses have started to narrow recently, yet profitability still looks some distance away and will depend on reaching larger volumes and keeping expenses tightly controlled.

Balance Sheet

Balance Sheet The balance sheet is relatively light, consistent with a software‑driven healthcare company. Total assets and shareholders’ equity have increased over time, indicating ongoing investment funded mainly by equity rather than heavy borrowing. Cash on hand is limited but not negligible, and debt is present but not dominant relative to overall assets. The company still relies on external capital to support operations, so balance‑sheet strength will hinge on maintaining access to funding until the business can sustain itself.

Cash Flow

Cash Flow DarioHealth has been burning cash consistently, with operating cash flows negative each year. Capital spending is very low, so nearly all the cash usage comes from funding operating losses rather than big physical investments. The pace of cash burn has eased somewhat, but the business is not yet self‑funding, which introduces financing and dilution risk if progress toward positive cash flow takes longer than planned.

Competitive Edge

Competitive Edge The company operates in a crowded digital health and chronic‑care management market, but it has carved out a differentiated niche. Its strengths include a multi‑condition platform (covering metabolic, musculoskeletal, and behavioral health), strong clinical evidence, and a business model focused on employers, health plans, and pharma partners rather than just individual consumers. The recent integration of Twill’s mental health tools deepens its behavioral offering, which is an important differentiator. However, competition from larger, better‑funded digital health and traditional healthcare players remains a key ongoing challenge.

Innovation and R&D

Innovation and R&D Innovation is clearly at the center of the strategy. DarioHealth combines connected devices, AI‑driven personalization, and human coaching into a single, integrated experience. It continues to expand into areas like GLP‑1 support, fall‑risk assessment, and deeper behavioral health, often via partnerships and acquisitions. The large library of clinical studies supports the platform’s claims and helps with payer and employer adoption. The trade‑off is that sustained R&D and integration work keep spending high, so the company must balance innovation with a credible path toward operating efficiency.

Summary

DarioHealth is an early‑stage digital therapeutics platform with growing but still modest revenue, ongoing losses, and steady cash burn, offset by a reasonably clean balance sheet and modest leverage. Its strategic strengths lie in an integrated, multi‑condition offering, robust clinical validation, and a B2B2C go‑to‑market model enhanced by the Twill acquisition. The main risks are execution and financing: turning clinical and product strengths into scale and positive cash flow before cash resources become tight. The announced strategic review adds another layer of uncertainty but could also reshape the company’s future direction, whether as an independent operator or as part of a larger healthcare platform.

NEWS

November 24, 2025 · 8:00 AM UTC

DarioHealth Announces Publication of Sanofi Study in JMIR Demonstrating an Estimated $5,077 Medical Cost Savings Per Dario Digital Health Platform User Per Year

Read more

November 13, 2025 · 6:30 AM UTC

DarioHealth Reports Third Quarter 2025 Financial and Operating Results

Read more

November 12, 2025 · 8:30 AM UTC

DarioHealth Presents New Data Demonstrating Significant Reduction in Medical Costs Among Employer Populations Using Its Digital Health Platform

Read more

November 6, 2025 · 8:30 AM UTC

DarioHealth to Report Third Quarter 2025 Results on Thursday, November 13, 2025

Read more

October 29, 2025 · 10:32 AM UTC

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of DarioHealth Corp. (NASDAQ: DRIO)

Read more